Ads
related to: abbvie jobs dublin ca area- Latest Jobs in Chicago
Right role for the right Candidate
Explore millions of Vacancies
- Jobs in California
Explore the lastes jobs
in your City
- Jobs in New York City, ny
Find the right Opportunity
for You
- Latest Jobs in Virginia
All available Jobs listed
Explore millions of Vacancies
- Latest Jobs in Chicago
jobs2careers.com has been visited by 100K+ users in the past month
Large Employment Site (>10 Million Unique Visitors Per Month) - TAtech
Search results
Results from the WOW.Com Content Network
Zeltiq Aesthetics is a subsidiary of AbbVie based in Pleasanton, California that markets and licenses devices used for cryolipolysis procedures. The company was founded in 2005 and raised $75 million in funding before going public in 2011. It was acquired by Allergan in February 2017 for $2.48 billion.
In June, Abbvie acquired TeneoOne and its lead compound TNB-383B. The compound is a BCMA-targeting immunotherapeutic for relapsed or refractory multiple myeloma. [30] In March 2022, AbbVie acquired Syndesi Therapeutics for up to $1 billion and its portfolio of novel modulators of the synaptic vesicle protein 2A and lead compound SDI-118.
Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, in the United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products.
The Tri-Valley area is also serviced by BART, offering service to the rest of the San Francisco Bay Area via two stops: West Dublin/Pleasanton and the Dublin/Pleasanton terminus station. [7] The West Dublin/Pleasanton Station opened in 2011, and was the first infill station on an existing line.
Actavis Generics [1] (formerly known as Watson Pharmaceuticals and Actavis plc, prior to the acquisition of Irish-based Allergan, Inc.) is a global pharmaceutical company focused on acquiring, developing, manufacturing and marketing branded pharmaceuticals, generic and over-the-counter medicines, and biologic products.
On June 16, 2010, Neurocrine agreed to a deal with AbbVie Inc. (previously Abbott Laboratories) [21] worth up to $575 million with Neurocrine granting AbbVie the worldwide rights to develop and commercialize elagolix, an oral gonadotropin-releasing hormone (GnRH) antagonist to treat endometriosis and uterine fibroids. [22]